{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:15:17Z","timestamp":1778001317077,"version":"3.51.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012589","name":"Fondation de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004889","name":"Fondation du CHU de Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004889","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Optimal cefazolin dosing for surgical prophylaxis in patients with severe obesity remains controversial, particularly regarding tissue exposure at the surgical site. Plasma concentrations may not reliably reflect pharmacologically active antibiotic levels in target tissues. This study aims to characterize total and calculated unbound concentrations of cefazolin in subcutaneous adipose tissue, dermis and plasma in patients with severe obesity undergoing bariatric surgery, and to assess pharmacodynamic target attainment across clinically relevant MIC thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective observational study, patients undergoing sleeve gastrectomy received cefazolin prophylaxis according to current guidelines (2 or 3\u2005g intravenously). Plasma, dermis and adipose tissue samples were collected at incision (T0), 30\u2005min (T30) and end of surgery (Tend). Total cefazolin concentrations were quantified using validated HPLC methods. Concentration\u2013time profiles were analysed using linear mixed\u2013effects models adjusted for age, BMI and creatinine clearance. Target attainment was evaluated at MIC thresholds of 2, 4 and 8\u2005mg\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dermis and plasma total cefazolin concentrations consistently exceeded all MIC thresholds in both dosing groups, whereas adipose tissue concentrations were more variable, with reduced attainment at higher MICs. Calculated unbound cefazolin concentrations demonstrated marked matrix\u2013dependent differences: plasma unbound levels consistently exceeded all targets, dermal unbound concentrations increased significantly from T0 to Tend and adipose tissue unbound concentrations remained low across all time points. Increasing the dose from 2 to 3\u2005g modestly improved total adipose tissue target attainment but did not substantially enhance unbound adipose tissue exposure. No surgical site infections occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with severe obesity, guideline\u2013recommended cefazolin dosing provides adequate plasma and dermis exposure but fails to ensure reliable unbound adipose tissue concentrations. These findings highlight the limitations of plasma-based assessments and support tissue\u2013informed, individualized prophylactic strategies in bariatric surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag150","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:42:31Z","timestamp":1776253351000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1060-5363","authenticated-orcid":false,"given":"Alexandra","family":"Porlier","sequence":"first","affiliation":[{"name":"Centre de recherche de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Nadeau","sequence":"additional","affiliation":[{"name":"Centre de recherche de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Laflamme","sequence":"additional","affiliation":[{"name":"Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval (IUCPQ-ULaval) , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"Centre de recherche du Centre hospitalier universitaire de Qu\u00e9bec, Universit\u00e9 Laval (CRCHU de Qu\u00e9bec-ULaval) , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Pilote","sequence":"additional","affiliation":[{"name":"Centre de recherche de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gervais","sequence":"additional","affiliation":[{"name":"Centre de recherche de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval (IUCPQ-ULaval) , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"Centre de recherche du Centre hospitalier universitaire de Qu\u00e9bec, Universit\u00e9 Laval (CRCHU de Qu\u00e9bec-ULaval) , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Drolet","sequence":"additional","affiliation":[{"name":"Centre de recherche de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"Facult\u00e9 de pharmacie, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-1000","authenticated-orcid":false,"given":"Andr\u00e9","family":"Tchernof","sequence":"additional","affiliation":[{"name":"Centre de recherche de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"\u00c9cole de Nutrition, Facult\u00e9 des sciences de l\u2019agriculture et de l\u2019alimentation, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Biertho","sequence":"additional","affiliation":[{"name":"Centre de recherche de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval (IUCPQ-ULaval) , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"D\u00e9partement de chirurgie, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Marceau","sequence":"additional","affiliation":[{"name":"Centre de recherche de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval (IUCPQ-ULaval) , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"D\u00e9partement de chirurgie, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantale","family":"Simard","sequence":"additional","affiliation":[{"name":"Centre de recherche de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"Facult\u00e9 de pharmacie, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Julien","sequence":"additional","affiliation":[{"name":"Centre de recherche de l\u2019Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval (IUCPQ-ULaval) , Qu\u00e9bec, QC ,","place":["Canada"]},{"name":"D\u00e9partement de chirurgie, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Laval , Qu\u00e9bec, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2026050512380410200_dkag150-B1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2146\/ajhp120568","article-title":"Clinical practice guidelines for antimicrobial prophylaxis in surgery","volume":"70","author":"Bratzler","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"2026050512380410200_dkag150-B2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1089\/sur.2012.167","article-title":"Effectiveness of pre-operative cefazolin in obese patients","volume":"15","author":"Unger","year":"2014","journal-title":"Surg Infect (Larchmt)"},{"key":"2026050512380410200_dkag150-B3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1089\/sur.2016.182","article-title":"Association between pre-operative cefazolin dose and surgical site infection in obese patients","volume":"18","author":"Peppard","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"key":"2026050512380410200_dkag150-B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/sur.2010.097","article-title":"Cefazolin dosing for surgical prophylaxis in morbidly obese patients","volume":"13","author":"Ho","year":"2012","journal-title":"Surg Infect (Larchmt)"},{"key":"2026050512380410200_dkag150-B5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00228-011-1048-x","article-title":"Pharmacokinetics and protein binding of cefazolin in morbidly obese patients","volume":"67","author":"Van Kralingen","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"2026050512380410200_dkag150-B6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ijantimicag.2016.08.019","article-title":"Evaluation of total body weight and body mass index cut-offs for increased cefazolin dose for surgical prophylaxis","volume":"48","author":"Hites","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2026050512380410200_dkag150-B7","author":"ASMBS"},{"key":"2026050512380410200_dkag150-B8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1086\/501572","article-title":"The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs","volume":"20","author":"Kirkland","year":"1999","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026050512380410200_dkag150-B9","doi-asserted-by":"publisher","DOI":"10.1590\/0100-6991e-20192252","article-title":"Surgical site infection in bariatric surgery: results of a care bundle","volume":"46","author":"Ferraz","year":"2019","journal-title":"Rev Col Bras Cir"},{"key":"2026050512380410200_dkag150-B10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jama.2022.24075","article-title":"Surgical site infection prevention: a review","volume":"329","author":"Seidelman","year":"2023","journal-title":"JAMA"},{"key":"2026050512380410200_dkag150-B11","doi-asserted-by":"publisher","DOI":"10.1177\/00469580231216400","article-title":"Compliance with guidelines of hypertension management, and associated factors among the health practitioners","volume":"60","author":"Ataro","year":"2023","journal-title":"Inquiry"},{"key":"2026050512380410200_dkag150-B12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/0306-4522(86)90259-9","article-title":"Serial reconstruction of Lucifer yellow-labeled supraoptic nucleus neurons in perfused rat hypothalamic explants","volume":"17","author":"Randle","year":"1986","journal-title":"Neuroscience"},{"key":"2026050512380410200_dkag150-B13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","article-title":"Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review","volume":"47","author":"Alobaid","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2026050512380410200_dkag150-B14","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1007\/s11695-022-06196-5","article-title":"Prophylactic cefazolin dosing in obesity-a systematic review","volume":"32","author":"Coates","year":"2022","journal-title":"Obes Surg"},{"key":"2026050512380410200_dkag150-B15","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00419-22","article-title":"Plasma and interstitial fluid pharmacokinetics of prophylactic cefazolin in elective bariatric surgery patients","volume":"66","author":"Ryan","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050512380410200_dkag150-B16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/jac\/dkt444","article-title":"Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis","volume":"69","author":"Brill","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026050512380410200_dkag150-B17","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s11695-016-2331-9","article-title":"Optimal cefazolin prophylactic dosing for bariatric surgery: no need for higher doses or intraoperative redosing","volume":"27","author":"Chen","year":"2017","journal-title":"Obes Surg"},{"key":"2026050512380410200_dkag150-B18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac105","article-title":"Safety and effectiveness of high-dose cefazolin in patients with high body weight: a retrospective cohort study","volume":"9","author":"Ryu","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026050512380410200_dkag150-B19","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.bja.2024.11.044","article-title":"Evaluation of the need for dosing adaptations in obese patients for surgical antibiotic prophylaxis: a model-based analysis of cefazolin pharmacokinetics","volume":"134","author":"Bindellini","year":"2025","journal-title":"Br J Anaesth"},{"key":"2026050512380410200_dkag150-B20","author":"EUCAST"},{"key":"2026050512380410200_dkag150-B21","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/ALN.0000000000005410","article-title":"Surgical antibiotic prophylaxis dosing in adult patients with obesity: a comprehensive review of pharmacokinetic and pharmacodynamic data","volume":"142","author":"Nothofer","year":"2025","journal-title":"Anesthesiology"},{"key":"2026050512380410200_dkag150-B22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3390\/antibiotics14121227","article-title":"Peri-operative dosage and therapeutic concentrations of cefazolin administered for surgical site infection prophylaxis in elective surgery\u2014A systematic review","volume":"14","author":"Ryan","year":"2025","journal-title":"Antibiotics"},{"key":"2026050512380410200_dkag150-B23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.bja.2017.10.023","article-title":"Cefazolin tissue concentrations with a prophylactic dose administered before sleeve gastrectomy in obese patients: a single centre study in 116 patients","volume":"120","author":"Cinotti","year":"2018","journal-title":"Br J Anaesth"},{"key":"2026050512380410200_dkag150-B24"},{"key":"2026050512380410200_dkag150-B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2026050512380410200_dkag150-B26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026050512380410200_dkag150-B27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.2146\/ajhp080200","article-title":"Estimation of creatinine clearance in morbidly obese patients","volume":"66","author":"Demirovic","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"2026050512380410200_dkag150-B28","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1053\/j.ackd.2010.05.010","article-title":"Estimating the glomerular filtration rate in obese adult patients for drug dosing","volume":"17","author":"Pai","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"2026050512380410200_dkag150-B29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ekir.2024.01.039","article-title":"Implications of implementing the 2021 CKD-EPI equation without race on managing patients with kidney disease in British Columbia, Canada","volume":"9","author":"Atiquzzaman","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026050512380410200_dkag150-B30","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/ajhp\/zxad132","article-title":"Stability and compatibility study guidelines for AJHP","volume":"80","author":"McPherson","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"2026050512380410200_dkag150-B31","doi-asserted-by":"publisher","first-page":"19763","DOI":"10.1038\/s41598-021-99162-7","article-title":"Population pharmacokinetic model of cefazolin in total hip arthroplasty","volume":"11","author":"Lanoisel\u00e9e","year":"2021","journal-title":"Sci Rep"},{"key":"2026050512380410200_dkag150-B32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/jac\/dkm476","article-title":"Tissue concentrations: do we ever learn?","volume":"61","author":"Mouton","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2026050512380410200_dkag150-B33","first-page":"23","article-title":"Pharmacokinetics of antibiotics in tissues and tissue fluids: a review","volume":"74","author":"Cars","year":"1990","journal-title":"Scand J Infect Dis Suppl"},{"key":"2026050512380410200_dkag150-B34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/sur.2019.039","article-title":"Lack of pharmacokinetic basis of weight-based dosing and intra-operative re-dosing with cefazolin surgical prophylaxis in obese patients: implications for antibiotic stewardship","volume":"20","author":"Blum","year":"2019","journal-title":"Surg Infect (Larchmt)"},{"key":"2026050512380410200_dkag150-B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106751","article-title":"Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight","volume":"61","author":"Chung","year":"2023","journal-title":"Intl J of Antimicrob Agents"},{"key":"2026050512380410200_dkag150-B36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1345\/aph.1D251","article-title":"Once-daily cefazolin and probenecid for skin and soft tissue infections","volume":"38","author":"Cox","year":"2004","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/5\/dkag150\/68221103\/dkag150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/5\/dkag150\/68221103\/dkag150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:38:07Z","timestamp":1777999087000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag150\/8669747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag150","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,3]]},"article-number":"dkag150"}}